Pioneer in Medical Device Media Reports

Share Professional Medical Device Knowledge

2025Year4Month2Date, Johnson & Johnson Medical Technologies (New York Stock Exchange Code:JNJ) at the European Heart Rhythm Association (EHRA) congress held in Vienna, Austria (EHRA) Annual Meeting,Published itsThermoCool SmartTouch SFCatheterSmartfIREClinical Trials12Months of data show that the dual-energy ablation technology demonstrates high efficiency and safety in treating patients.

According to the data published by Johnson & Johnson Medical, when the recommended ablation parameters are strictly followed during treatment,ThermoCool SmartTouch SFThe efficiency of the catheter is as high as86.9%. This catheter is the first to integrate dual-energy pulsed field ablation (PFA) and Radiofrequency (RF) Ablation technology catheter, equipped withPFAndRFAblation Index, Aimed at Improving the Effectiveness and Safety of Ablation Therapy.

In addition to high efficiency, clinical studies have also shown that patients who undergo ablation treatment using this catheter have a reduced total reliance on antiarrhythmic drugs (AAD) has significantly decreased in usage. At the same time, researchers have also observed clinically meaningful improvements in patients' quality of life, as well as a reduction in healthcare utilization. These data provide2024Year4Published in the month ofSmartfIREThe results of the clinical trial provided strong supplementary evidence.

ThermoCool SmartTouch SFCatheter &TruPulseUsed in conjunction with the generator, both of which can be used withCarto 3The electroanatomical mapping system is fully integrated, providing clinicians with more precise and efficient ablation treatment options. Notably, the catheter has been2024Year12Month ObtainedCEMark, but still in the research stage in the United States.

In12In the follow-up of months, the research results showed that under the strict monitoring required by the protocol, the non-recurrence rate was71.5%. However, in patients who were treated with a high level of adherence to the recommended ablation workflow, this proportion increased to86.9%。In addition, Johnson & Johnson also reported3.6%The incidence of severe device-related adverse events, none of which were associated withPFEnergy-related. Compared to baseline, the cardiovascular-related hospitalization rate was relatively reduced.40.8%，I/IIIClassAADRelatively reduced use60.4%。

Aalst, BelgiumOLVDr. Tom De Potter, Director and Deputy Director of the Hospital's Heart Center, said: "With a high level of adherence to the recommended ablation protocol (utilizingPFAndRFLabel Index)12Months ofSmartfIREThe data shows86.9%The effectiveness rate fully supports dual-energyThermoCool SmartTouch SFThe effectiveness, safety, and clinical benefits of catheters in ablation therapy."

In addition, Johnson & Johnson Medical Technologies is alsoEHRAAnnounced at the annual meeting its sponsorship ofREAL AFReal-world evidence from registration studies. The study included68Data from the Home Center aims to investigate the real-world safety and effectiveness of catheter ablation procedures, health outcomes, and the future of electrophysiology practice.REAL AFThe data include the impact of gender differences on the outcomes of ablation strategies, as well as the comparison results between zero-fluoroscopy and conventional methods.

Jennifer, Vice President of Johnson & Johnson Medical Technologies and Head of Scientific Affairs· Culin said, "We recognize that advancing patient care requires strong collaboration and rigorous clinical research. By supporting initiatives likeGPfIRE"Through such research, we are committed to generating solid clinical evidence, particularly regarding pulsed field ablation. This evidence will not only support treatment decisions but also drive innovation in atrial fibrillation care. Our goal is to provide clinicians with the insights needed to optimize workflows and improve patient outcomes."

In summary, Johnson & Johnson Medical Technologies announcedThermoCool SmartTouch SFCatheterSmartfIREClinical Trials12The monthly data demonstrate the efficiency and safety of this dual-energy ablation technology in treating patients. In the future, with further research and the accumulation of clinical evidence, this technology is expected to offer better treatment options and clinical outcomes for patients with atrial fibrillation.